Promethazine


Description

A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.

Read more

Pharmacology

Indication

For the treatment of allergic disorders, and nausea/vomiting.

Pharmacodynamic

Promethazine, a phenothiazine, is an H1-antagonist with anticholinergic, sedative, and antiemetic ef... Read more

Mechanism of action

Like other H1-antagonists, promethazine competes with free histamine for binding at H1-receptor site... Read more

Absorption

On average, 88% of a promethazine dose is absorbed after oral administration; however, the absolute... Read more

Protein binding

93%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

16-19 hours

Route of elimination

Promethazine hydrochloride is metabolized in the liver, with the sulfoxides of promethazine and N-de... Read more

Toxicity

Symptoms of overdose include mild depression of the central nervous system and cardiovascular system... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Insomnia US
Varying Reports
Tremors US
Varying Reports
Convulsive seizures US
Varying Reports
Oculogyric crises US
Varying Reports
Excitation US
Varying Reports
Catatonic-like states US
Varying Reports
Hysteria US
Varying Reports
Hallucinations US
Varying Reports
Lassitude US
Varying Reports
Tinnitus US
Varying Reports
Incoordination US
Varying Reports
Fatigue US
Varying Reports
Blurred vision US
Varying Reports
Euphoria US
Varying Reports
Diplopia US
Varying Reports
Nervousness US
Varying Reports
Drowsiness US
Varying Reports
Dizziness US
Varying Reports
Extrapyrimidal reactions US
Varying Reports
Thrombocytopenic Purpura US
Varying Reports
Agranulocytosis US
Varying Reports
Leukopenia US
Varying Reports
Angioneurotic Edema US
Varying Reports
Photosensitivity US
Varying Reports
Asthma US
Varying Reports
Dermatitis US
Varying Reports
Urticaria US
Varying Reports
Agitated Behavior US
Varying Reports
Delirium US
Varying Reports
Nightmares US
Varying Reports
Respiratory Depression US
Varying Reports
Abnormal movement US
Varying Reports
Hyperexcitability US
Varying Reports
Nasal Stuffiness US
Varying Reports
Jaundice US
Varying Reports
Tachycardia US
Varying Reports
Bradycardia US
Varying Reports
Confusion US
Varying Reports
Disorientation US
Varying Reports
Blurred vision US
Varying Reports
Dizziness US
Varying Reports
Sedation US
Varying Reports
Somnolence US
Varying Reports
Dry Mouth US
Varying Reports
Jaundice US
Varying Reports
Nausea US
Varying Reports
Vomiting US
Varying Reports
Increases in blood pressure US
Varying Reports
Decreases in blood pressure US
Varying Reports
Faintness US
Varying Reports

Contraindications

  • Regions: US
  • Age Groups:
    • pediatric
  • Below Age:
    • Amount: 2
    • Unit: year
  • Route:
    • Oral
    • Intravenous
    • Intramuscular
  • Dose Form:
    • Injection
  • Regions: US
  • Patient Conditions:
      • Name: Comatose states
      • Drugbank Id: DBCOND0107802
  • Route:
    • Intravenous
    • Intramuscular
  • Dose Form:
    • Injection
  • Regions: US
  • Patient Conditions:
      • Name: Subcutaneous route of administration
      • Drugbank Id: DBCOND0108186
  • Route:
    • Intravenous
    • Intramuscular
  • Dose Form:
    • Injection
  • Regions: US
  • Patient Conditions:
      • Name: Intra-arterial route of administration
      • Drugbank Id: DBCOND0108185
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Asthma
      • Drugbank Id: DBCOND0013565
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Lower respiratory tract symptoms
      • Drugbank Id: DBCOND0108184

Food Interactions

  • Take with food to reduce irritation. Avoid alcohol.

Interactions

Type in a drug name to check for interaction with Promethazine

The metabolism of (R)-warfarin can be decreased when combined with Promethazine.
The metabolism of (S)-Warfarin can be decreased when combined with Promethazine.
The therapeutic efficacy of Promethazine can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Promethazine.
2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Promethazine.
4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Promethazine.
The risk or severity of adverse effects can be increased when Promethazine is combined with 4-hydroxycoumarin.
The risk or severity of adverse effects can be increased when Promethazine is combined with 4-Methoxyamphetamine.
The risk or severity of adverse effects can be increased when Promethazine is combined with 5-methoxy-N,N-dimethyltryptamine.
The risk or severity of adverse effects can be increased when Promethazine is combined with 7-Nitroindazole.
The risk or severity of adverse effects can be increased when Promethazine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Abacavir may decrease the excretion rate of Promethazine which could result in a higher serum level.
Promethazine can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
The metabolism of Promethazine can be increased when combined with Abatacept.
The risk or severity of Tachycardia can be increased when Promethazine is combined with Abediterol.
The serum concentration of Abemaciclib can be increased when it is combined with Promethazine.
The risk or severity of QTc prolongation can be increased when Promethazine is combined with Abexinostat.
The metabolism of Promethazine can be decreased when combined with Abiraterone.
Acarbose may decrease the excretion rate of Promethazine which could result in a higher serum level.
The serum concentration of Acebutolol can be increased when it is combined with Promethazine.

References

  • 1 . Peters RJ Jr, Kelder SH, Markham CM, Yacoubian GS Jr, Peters LA, Ellis A: Beliefs and social norms about codeine and promethazine hydrochloride cough syrup (CPHCS) onset and perceived addiction among urban Houstonian adolescents: an addiction trend in the city of lean. J Drug Educ. 2003;33(4):415-25. [PubMed: 15237866]

Recent Questions